ICTHIOVAC VR/PD, EMULSION FOR INJECTION FOR SEA BASS

Authorised

- Photobacterium damselae, subsp. Piscicida, strain DI21, Inactivated
- Vibrio anguillarum, serotype O1, Inactivated
- Vibrio anguillarum, serotype O2b, Inactivated
- Vibrio anguillarum, serotype O2a, Inactivated

Product identification

Medicine name:
ICTHIOVAC VR/PD, EMULSION FOR INJECTION FOR SEA BASS
ICTHIOVAC VR/PD, emulzija za injekciju, za lubine

Active substance:
Photobacterium damselae, subsp. Piscicida, strain DI21, Inactivated

Vibrio anguillarum, serotype O1, Inactivated

Vibrio anguillarum, serotype O2b, Inactivated

Vibrio anguillarum, serotype O2a, Inactivated

Target species:
Seabass

Route of administration:
Intraperitoneal use

Product details

Active substance and strength:

Photobacterium damselae, subsp. Piscicida, strain DI21, Inactivated
60.00 Relative Percentage Survival / 1.00 Dose

Vibrio anguillarum, serotype O1, Inactivated
75.00 Relative Percentage Survival / 1.00 Dose

Vibrio anguillarum, serotype O2b, Inactivated
75.00 Relative Percentage Survival / 1.00 Dose

Vibrio anguillarum, serotype O2a, Inactivated
75.00 Relative Percentage Survival / 1.00 Dose

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intraperitoneal use:

- **Seabass**
  - Fish meat. 0 degree day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI10X

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Croatia

Package description:

Available only in Croatian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Laboratorios Hipra S.A.

Marketing authorisation date:
18/05/2017

Manufacturing sites for batch release:
Laboratorios Hipra S.A.

Responsible authority:
Ministry Of Agriculture Veterinary And Food Safety Directorate

Authorisation number:
UP/I-322-05/22-01/285

Date of authorisation status change:
16/03/2023

Reference member state:
France

Procedure number:
FR/V/0314/001

Concerned member states:
Croatia Cyprus Greece Italy Portugal Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
